Every wafer that leaves Science Foundry must pass our engineers' inspection.

We are thrilled to welcome Nevada Sanchez as Executive Vice President of Engineering. Nevada co-founded Butterfly Network where he conceived the world’s first ultrasound system on a chip and built the engineering organization that took it from a prototype to a globally deployed platform.

Science Welcomes Nevada Sanchez as Executive Vice President of Engineering | Science Corporation

Science Corporation is a clinical-stage medical technology company.

science.xyz

PRIMA received its CE mark, authorizing commercial use across Europe. Frank Brodie, Science's Medical Director for Vision and PRIMA, shares what this milestone means after a career treating geographic atrophy patients who can now benefit from PRIMA for the first time.

PRIMA has received two Humanitarian Use Device designations from the FDA, one for advanced geographic atrophy and one for Stargardt disease. Extensive research and clinical work have led to these HUD designations, establishing a clear regulatory path for PRIMA to reach patients in the US.

PRIMA Has Received Humanitarian Use Device Designations from the US Food and Drug Administration | Science Corporation

Science Corporation is a clinical-stage medical technology company.

science.xyz

Die CE Kennzeichnung läutet die Europa- Markteinführung von PRIMA ein, der ersten und einzigen Therapie, die das funktionelle zentrale Sehvermögen von Patienten mit geografischer Atrophie, die durch trockene altersbedingte Makuladegeneration verursacht wird, wiederherstellen kann.

Today marks the European launch of PRIMA, the first and only treatment to be commercially available that restores functional central vision to patients with geographic atrophy caused by dry age-related macular degeneration, a leading cause of blindness.

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Frank Brodie, MD, Science’s Medical Director for Vision, about our PRIMA implant, the first treatment shown in clinical trials to restore functional vision for geographic atrophy due to AMD.

The Retina TL;DR with Dr. Weng: Restoring central vision in geographic atrophy with PRIMA and Frank Brodie, MD, MBA | Eye Care Network - Ophthalmology Times

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Brodie about a photovoltaic subretinal implant showing meaningful visual gains in…

ophthalmologytimes.com

New 36-month clinical data for our PRIMA retinal implant will be presented for the first time at the 26th EURETINA Congress in Vienna, October 1-4 by Mahi Muqit, MD, co-author of the New England Journal of Medicine peer-reviewed original paper on the PRIMA.

Watch metal ions play atomic-scale billiards. That pink glow is a cloud of metal atoms bouncing off gas molecules as they deposit on a wafer.

In a San Francisco Chronicle front page story about the PRIMA retinal implant, our Medical Director for Vision Dr. Frank Brodie discusses how, in clinical trials, it helped restore meaningful vision to people living with geographic atrophy due to age-related macular degeneration.

Our Chief Scientific Officer and co-founder Alan Mardinly spoke at Frontiers of Neuro during Deep Tech Week in San Francisco to discuss Science’s work on PRIMA and Biohybrid.

The blade spins at 30,000 RPM through a wafer of exploratory biohybrid neural probes. They survive only if the water moves faster than the heat.

Frank Brodie, MD, Science's Medical Director for Vision and PRIMA, was honored with the Ascent to Excellence Award at the annual CTS Retina Meeting, which brings together retina specialists and industry partners to discuss advances in clinical research.

Scientific American spotlights “Icons,” including Science CEO Max Hodak, who share their thoughts on the state of American science. Max discussed how AI is opening new frontiers across medicine, the shifting funding landscape in American science, and where neural engineering is headed.

Science Corporation CEO co-founder Max Hodak on why U.S. science needs reform

The Science Corporation CEO and Neuralink co-founder on how artificial intelligence is the new industrial revolution

scientificamerican.com

Watch a neural recording system small enough to fit in your pocket get built.

Science CEO Max Hodak joined Ashlee Vance for Core Memory’s first live event for a conversation on neural engineering, the science of restoring vision, and where the field is headed.

What Happens When We Stop Dying? - Max Hodak Live

YouTube video by Core Memory Podcast

youtube.com

Geographic atrophy due to AMD is a leading cause of irreversible blindness, affecting more than 5 million people. Popular Mechanics looks at the breakthroughs redefining vision restoration, including our PRIMA retinal implant, shown in @NEJM clinical trials to restore meaningful central vision.

These Breakthroughs Could Restore Sight for Millions of People

Revolutionary devices, age rewinding, and cell regeneration: scientists are finding multiple promising approaches for curing blindness, and even for stopping vision loss before it starts.

popularmechanics.com

Science CEO Max Hodak joined @semafor.com Tech Editor Reed Albergotti on stage at First Principles for a wide-ranging conversation on longevity, Science's PRIMA retinal prosthesis and Vessel organ perfusion programs, and the philosophy of identity and BCI.

Science CEO Max Hodak spoke at TECH by Handelsblatt about the PRIMA implant for blindness caused by AMD/GA – and the landmark clinical trial published in The NEJM. Germany has been a partner in this work from the beginning and we expect it to be the first market where PRIMA is available at scale.

What does it take to build glasses that follow your eye movements? Watch our team integrate eye-tracking cameras into the next-generation PRIMA Glasses so patients can look around naturally.

Congratulations to Daniel Palanker, PRIMA original inventor and professor of ophthalmology at Stanford University, on receiving the 2027 Friedenwald Award from the @arvoinfo.bsky.social, one of the highest honors in ophthalmic research.

Science CEO, Max Hodak will join Handelsblatt’s Felix Holtermann at TECH by Handelsblatt on Monday to discuss the future of brain-computer interfaces. Max recently spoke with Handelsblatt about our PRIMA retinal implant.

Gehirnchips: Der Wettlauf um das beste Implantat für das menschliche Hirn

Max Hodak hat Elon Musks Neuralink mitgegründet. Mit seiner Firma Science Corp arbeitet er daran, Blinden das Sehen zurückzugeben. Und ist damit nicht der einzige, der auf neue Gehirnchips setzt.

handelsblatt.com

Our team working on the next-generation PRIMA Glasses is focused on creating the best patient experience. How? By leveraging the “smartphone dividend.” Watch.

At Science, our cell engineers create neurons from stem cells. See what it looks like.

“Max Hodak is working on the future … The first practical test for this goal is a product called ‘PRIMA’—a microchip smaller than a grain of rice that is implanted not in the brain, but under the retina. Our CEO, Max Hodak, spoke with Handelsblatt about our PRIMA retinal implant.

Gehirnchips: Der Wettlauf um das beste Implantat für das menschliche Hirn

Max Hodak hat Elon Musks Neuralink mitgegründet. Mit seiner Firma Science Corp arbeitet er daran, Blinden das Sehen zurückzugeben. Und ist damit nicht der einzige, der auf neue Gehirnchips setzt.

handelsblatt.com

What key principles should govern the rights of BCI patients? Our Chief Legal Officer Alex Feerst wrote about it here science.xyz/news/bci-pri.... Today he is joined by Science's Director of BCI Research Emma Zhou at The Cognitive Frontier in San Francisco to discuss.

Brain-Computer Interfaces and Patients' Rights: Some Key Principles | Science Corporation

Science Corporation is a clinical-stage medical technology company.

science.xyz

Construction is underway at our updated Science Foundry facility in Durham, NC for the manufacture of next-generation BCI devices.

Prof. Boris Stanzel (Eye Clinic Sulzbach, Knappschaft Hospital Saar & Department of Ophthalmology, University of Bonn) presenting at ARVO 2026 (Association for Research in Vision and Ophthalmology) delivered one of ten PRIMA presentations.

ARVO brings together the world's leading vision researchers and clinicians each year. This week, PRIMA by Science was featured in ten presentations across clinical outcomes, device training, surgical technique, and imaging.

What does it take to engineer a smaller, lighter, and more ergonomic PRIMA? Watch Episode 1: Our team tackles the next generation PRIMA Glasses.